CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2022 | $36,000 | -5.3% | 600 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $38,000 | -70.3% | 600 | -64.7% | 0.00% | -66.7% |
| Q4 2021 | $128,000 | -52.2% | 1,700 | -29.2% | 0.00% | -50.0% |
| Q3 2021 | $268,000 | -28.0% | 2,400 | +4.3% | 0.01% | -25.0% |
| Q2 2021 | $372,000 | +291.6% | 2,300 | +196.8% | 0.01% | +300.0% |
| Q1 2021 | $95,000 | +55.7% | 775 | +93.8% | 0.00% | 0.0% |
| Q4 2020 | $61,000 | +74.3% | 400 | -50.0% | 0.00% | +100.0% |
| Q3 2018 | $35,000 | -25.5% | 800 | 0.0% | 0.00% | -50.0% |
| Q2 2018 | $47,000 | – | 800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |